Themis Medicare
- Market cap
- ₹ 826 Cr.
- P/E
- 36.1x
- P/B
- 2.19x
- 52-week range
- 64.95 – 140.6
- ROE
- 0%
- ROCE
- 3%
- Dividend yield
- 0.5%
- Debt / equity
- 0.25
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Themis Medicare Limited is a research-based pharmaceutical company, which is engaged in the manufacturing of pharmaceutical products, especially in formulation and active pharmaceutical ingredients (API) activity. The Company operates through one segment: Pharmaceuticals. The Company manufactures therapeutic pharma products, differential healthcare products, and APIs based in India. The Company specializes in manufacturing a range of products for application areas like pain management, critical care and anti-infectives. Its analgesic and anti-inflammatory products include Aquadol Tpm Gel, Etojet 90 10'S, Etojet 120 10'S, Etojet Mr Tablets 10'S, Etojet XP Gel, Themidol-P Tab 10's, Dhoom, Aquadol inj, Dyloaqua inj, Joydol -P, Joydol -SP, Joydol -TH, and Nimujet Gel. Its Analgesics products include Anemol, Tazowin, Themidol, Themidol. Its Anesthesia products include Bupicaine 0.25%, Ketmin 2 Vial, Ketmin 5, Ropicaine 2, Themicaine 2%, and more.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Themis Medicare against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)36.1 against a typical 34.6: pricier than most peers (1st = cheapest).119th of 220
- Sales growth−11.2% against a typical +15.6% from a year earlier.167th of 197
- Share price, 3 months−6.9% against a typical −0.5%.130th of 200
- Size₹ 826.2 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).91st of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Look closer
Rated BBB- to BB+ by 2 agencies- CARE lowered its rating on 8 Oct 2026.
- CARE lowered its rating on 8 Oct 2026. Acuite may follow.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE BB+ | Stable | 8 Oct 2026 |
| Acuite | ACUITE BBB- | Stable | 8 Jun 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 8 Oct 2026 | ▼ Downgrade1 notch | CARE BBB- → CARE BB+ | Medium | CARE | ₹ 125.89 Cr. | |
| 8 Jun 2026 | ▼ Downgrade1 notch | ACUITE BBB → ACUITE BBB- | — | Acuite | ₹ 129.1 Cr. | |
| 21 Aug 2025 | Reaffirmed | ACUITE BBB | — | Acuite | ₹ 129.1 Cr. | |
| 12 Aug 2025 | Reaffirmed | CARE BBB- | — | CARE | ₹ 125.89 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 5 Nov 2026Upcoming | Financial Results | To consider and approve the un-audited standalone and consolidated financial results for the period ended September 30, 2026 |
| 13 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 28 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 13 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 13 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 1 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 20 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 105 | 83 | 98 | 123 | 117 | 94 | 72 | 98 | 78 | 90 | 77 | 87 |
| Expenses | 92 | 74 | 89 | 94 | 100 | 88 | 79 | 108 | 81 | 80 | 73 | 139 |
| Operating Profit | 12 | 8 | 9 | 29 | 17 | 6 | −8 | −10 | −3 | 10 | 4 | −52 |
| OPM % | 12% | 10% | 10% | 24% | 15% | 6% | −11% | −10% | −4% | 11% | 4.9% | −60% |
| Other Income | 7 | 6 | 5 | 7 | 6 | 1 | 2 | 1 | 5 | 6 | 11 | 97 |
| Interest | 2 | 3 | 2 | 2 | 2 | 3 | 2 | 2 | 3 | 3 | 3 | 3 |
| Depreciation | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | 14 | 8 | 9 | 31 | 18 | 2 | −11 | −14 | −3 | 10 | 9 | 39 |
| Tax % | 19% | 10% | 24% | 21% | 20% | 69% | −13% | 1% | 5% | 3% | 2% | 36% |
| Net Profit | 11 | 7 | 7 | 25 | 14 | 1 | −10 | −14 | −4 | 10 | 9 | 25 |
| EPS in Rs | 1.23 | 0.8 | 0.72 | 2.68 | 1.55 | 0.06 | −1.05 | −1.54 | −0.39 | 1.1 | 0.97 | 2.67 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 4%
- 5 Years
- 8%
- 3 Years
- −1%
- TTM
- −13%
- 10 Years
- −20%
- 5 Years
- −46%
- 3 Years
- −69%
- TTM
- −321%
- 10 Years
- 7%
- 5 Years
- 0%
- 3 Years
- −14%
- TTM
- —
- 10 Years
- 11%
- 5 Years
- 12%
- 3 Years
- 6%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Themis Medicare | ₹ 99.90 | ₹ 826 Cr. | 36.1x | 2.2x | 0% | — |
| Aurobindo Pharma | ₹ 1,569.30 | ₹ 90,294 Cr. | 25.1x | 2.4x | 9.9% | 10.4% |
| Neuland Laboratories | ₹ 18,882.05 | ₹ 24,132 Cr. | 64.3x | 12.6x | 21.4% | 18% |
| Pfizer | ₹ 3,610.35 | ₹ 16,513 Cr. | 27.5x | 5x | 17.2% | 28.7% |
| Unichem Laboratories | ₹ 470.00 | ₹ 3,309 Cr. | 54.3x | 1.5x | 9.8% | 11.5% |
| Jagsonpal Pharmaceuticals | ₹ 213.00 | ₹ 1,402 Cr. | 34.3x | 5.4x | 16.7% | 15% |
Management
- Dinesh Shantilal Patel
- Executive Chairman of the Board
- Sachin Dinesh Patel
- Chief Executive Officer, Managing Director, Executive Director
- Tushar J. Dalal
- Chief Financial Officer
- Nagraj Mogaveera
- Interim Company Secretary, Compliance Officer
Prices are delayed and for information only. Nothing on this page is investment advice.